Bristol/ImClone Erbitux Sales Declining In Face Of Vectibix Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol-Myers Squibb/ImClone anti-EGFR biologic is facing additional challenges in 2007, including patent litigation.
You may also be interested in...
Vectibix Vs. Erbitux: The Race For A First-Line Colorectal Cancer Indication
Expansion into the first-line colorectal cancer setting offers a significant opportunity for Amgen and ImClone's respective EGFR inhibitors.
Vectibix Vs. Erbitux: The Race For A First-Line Colorectal Cancer Indication
Expansion into the first-line colorectal cancer setting offers a significant opportunity for Amgen and ImClone's respective EGFR inhibitors.
ImClone Reports Promising Erbitux First-Line Colorectal Cancer Results
Company will present data from the Phase III CRYSTAL study at ASCO in June.